IL18 and chronic kidney disease: The principal finding in this study is that IL-18 serum concentrations equal to or lower than the evaluated cut-off values may protect non-diabetic patients with varying stages of CKD and history of AMI in the previous year, against cardiovascular death in 2-year follow-up.